TuHURA Clears FDA Hurdle for VISTA-Inhibiting AML Therapy — TuHURA Biosciences, Inc.

Event summary

TuHURA Biosciences received FDA clearance for its IND application for TBS-2025, a VISTA-inhibiting antibody, to begin Phase 1b trials in relapsed/refractory mutNPM1 AML patients.
The study will evaluate TBS-2025's safety and efficacy as a monotherapy in patients who failed menin inhibitor therapy, an unmet medical need.
TuHURA is the only company advancing a VISTA-inhibiting monoclonal antibody through the FDA's IND process into a Phase 1b study in mutNPM1 AML.
Preclinical data showed TBS-2025 significantly improved survival in murine models of AML, comparable to intensive chemotherapy.

The big picture

TuHURA's FDA clearance for TBS-2025 marks a significant step in addressing the unmet need for treatments in relapsed/refractory mutNPM1 AML patients. The company's focus on overcoming resistance to cancer immunotherapy aligns with broader industry trends toward precision oncology and combination therapies. Success in this Phase 1b trial could position TuHURA as a key player in the AML space, particularly if TBS-2025 demonstrates efficacy in a patient population with limited treatment options.

What we're watching

Clinical Trial Execution: The pace at which TuHURA can enroll patients and progress to the dose-optimization stage of the Phase 1b trial will determine the timeline for potential accelerated approval discussions with the FDA.
Regulatory Strategy: Whether TuHURA can leverage encouraging response rates to expand the trial and pursue accelerated approval will be critical for the commercial potential of TBS-2025.
Competitive Positioning: How TuHURA's VISTA-inhibiting approach differentiates itself in the crowded AML treatment landscape, particularly against emerging menin inhibitors and other targeted therapies.